Summary
The in vitro chemosensitivity of a human lung cancer cell line to hydroxyurea (HU) was measured, and concentrations of 1 m M HU effected 99% inhibition of cell growth. Therefore, infusions designed to achieve serum levels of over 1 m M HU were assessed by escalating doses of hydroxyurea (HU) administered by continuous i. v. infusion at 3-weekly intervals in 18 patients with lung cancer. Dose increments from 24 g in 24 h to 48 g in 48 h were achieved. The dose-limiting toxicity at 48 g in 48 h was myelosuppression. Oral administration of HU did not result in sustained levels comparable to those achieved with continuous infusion. Two patients showed evidence of radiological response after three courses of treatment. Serum HU profiles were monitored after administration i. v. in 26 courses and after administration p. o. in 5 courses of treatment. A mean serum level of >1 mM was achieved by 6 h and then maintained during treatment. The standard error of the mean area under the curve showed an overall 5% variation. HU can be given in doses up to 48 g in 48 h 3-weekly with manageable tissue and bone marrow toxicity, and the in vivo blood levels attained are equal to those necessary for effective cell inhibition in an appropriate in vitro model. This schedule provides a basis for combination studies with other cytotoxics or for use of HU as a DNA repair inhibitor.
Similar content being viewed by others
References
Arul IM (1970) Therapeutic effects of hydroxyurea: experience with 118 patients with inoperable tumours. Cancer 25: 705–714
Belt RJ, Hass CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion. Cancer 46: 455–462
Borenfreund E, Krim M, Bendlich A (1969) Chromosomal aberrations induced by hyponitrite and hydroxylamine derivatives. J Natl Cancer Inst 32: 667–680
Creasy WA, Capizzi RL, DeConti RC (1970) Clinical and biochemical studies of high dose intermittent therapy of solid tumours with hydroxyurea (NSC-32065). Cancer Chemother Rep 54: 191–194
De Jaeger R, Longeval E, Klastersky J (1980) High dose cisplatin with fluid and mannitol induced diuresis in advanced lung cancer: a phase II trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 64: 1341–1346
Donehower RC (1982) Hydroxyurea. In: Chubner B (ed), Pharmacological principles of cancer treatment. Saunders, Philadelphia, pp 269–275
Fabricius E, Rajewsky MF (1971) Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Et Clin Biol 16: 679–683
Frindel E, Malaise E, Tubiana M (1968) Cell proliferation kinetics in five human solid tumours. Cancer 22: 611–620
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumours: establishment of cell lines derived from a series of solid tumours. J Natl Cancer Inst 51: 1417–1423
Kaung DT, Walsh WS, Sbor S, Patno ME (1968) Hydroxyurea in therapy for nonresectable cancer of the lung. Cancer Chemother Rep 52: 271–274
Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukaemia. Cancer 29: 1052–1056
Krakoff IH (1975) Clinical and pharmacological effects of hydroxyurea. In: Sartorelli AC, Johns DG (eds) Handbuch der experimentellen Pharmakologie, vol 38/II. Springer, Belin Heidelberg New York, pp 789–792
Landgren RC, Hussey DH, Barkley HT, Samuels ML (1974) Split course irradiation compared to split course irradiation plus hydroxurea in operable bronchogenic carcinoma: a randomised study of 53 patients. Cancer 34: 1598–1601
Lerner HJ, Beckloff GL (1965) Hydroxyurea administered intermittently. JAMA 192: 138–140
Le Par E, Faust DS, Brady LW, Beckloff GL (1967) Clinical evaluation of the adjunctive use of hydroxyurea in radiation therapy of carcinoma of the lung. A comparative study. Radiol Clin 36: 32–40
Martin RF, Radford J, Pardee M (1977) Accumulation of short DNA fragments in hydroxyurea treated mouse L cells. Biochem Biophys Res Commun 74: 9–15
Pearson CM (1983) In: Downes CS, Collins ARS, Johnson RT. International Workshop on DNA Repair. Mutat Res 112: 75–83
Sinclair WJ (1965) Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science 150: 1729–1731
Skipper HE, Schabel FM Jr, Wilcox WS (1967) Experimental evaluation of potential anticancer agents: XI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukaemia cells. Cancer Chemother Rep 51: 125–141
Synder RD (1984) Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphates. Cell Biol Toxicol 1: 81–93
Thelander L, Reichard P (1979) Reduction of ribonucleotides. Annu Rev Biochem 48: 133–158
Thurman WG, Bloedow C, Howe CD, Levin WC, Davis P, Lane M, Sullivan MP, Griffith KM (1963) A phase I study of hydroxyurea. Cancer Chemother Rep 29: 103–107
Tubiana M, Malaise EP (1976) Growth rate and cell kinetics in human tumours. In: Symington T, Carter RL (eds) Scientific foundations of oncology. Heinemann, London, pp 119–125
Wawra E, Wintersberger E (1983) Dose hydroxyurea inhibit DNa replication in mouse cells by more than one mechanism? Mol Cell Biol 3: 297–304
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva
Young CW, Hodge S (1964) Hydroxyurea: inhibitory effect on DNA metabolism. Science 146: 1172–1174
Young CW, Schachetman G, Karnofsky DA (1967) Hydroxy urea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res 27: 526–534
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Veale, D., Cantwell, B.M.J., Kerr, N. et al. Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother. Pharmacol. 21, 53–56 (1988). https://doi.org/10.1007/BF00262739
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262739